ERBB2 and neoplasm: The proposed mechanisms of action include the depletion of the surface HER2 levels on the HER2-overexpressing cells, the inhibition of the proteolytic elimination of the extracellular domain of HER2, and the augmentation of antibody-dependent cell-mediated phagocytosis (ADCP) by recruiting immune cells to the tumor.